Research paperUrinary-exosomal miR-2909: A novel pathognomonic trait of prostate cancer severity

- Urinary exosomal-miR-2909 recruitment distinguishes Prostate from Bladder cancer.
- Urinary exosomal-miR2909 level correlates with the severity of Prostate cancer in all its forms.
- Urinary exosomal-miR-2909 revealed a better diagnostic potential for Prostate cancer than either PSA or miR-615-3p.

The global occurrence of prostate cancer with a range of patient outcome has prompted various investigators to explore novel molecular biomarkers that can precisely detect and track this type of cancer severity. Several studies suggest that micro-RNAs have emerged to act as a new largely unexplored class of biomarkers because of their inherent stability, resilience and recruitment into exosomes present in various human body fluids. With this study, we aim to reveal the nature of urinary-exosomal miR-2909 & miR-615-3p recruitment in patients suffering from either prostate cancer (n = 90) or bladder cancer (n = 60) as compared to that in either prostate disease-control subjects having benign prostate hyperplasia (n = 10) or healthy subjects (n = 50). Unlike miR-615-3p, the urinary- exosomal miR-2909 recruitment was not only observed conspicuously in subjects having prostate cancer in comparison to bladder cancer but also the extent of urinary exosomal miR-2909 recruitment showed characteristic variation as a function of prostate cancer aggressiveness as compared to that of either urinary- exosomal miR-615-3p level or existing widely recognised serum prostate specifics antigen (PSA) biomarker of this cancer. In summary, we propose that the extent of urinary exosomal miR-2909 recruitment may provide a potential non-invasive candidate diagnostic marker for the detection of prostate cancer and its aggressiveness.